ODI Pharma: a unique position and exclusive supply of dried flower for Synoptis Pharma

Who is ODI Pharma and where does its raw material come from?

ODI Pharma AB is a Swedish company based in Stockholm, listed on Spotlight
Stock Market and has been operating since 2018. It does not cultivate itself. On its own website
it states that it does not intend to cultivate the raw material and sources it from partners, which in this
miejscu nie nazywa po imieniu.

The company presents itself as a manufacturer and representative of ready-made products
hemp for pharmaceutical purposes, operating through a network of subsidiaries
and partners. This description combines two roles at once: responsibility for the finished product
and mediation in trade. There is no cultivation involved, which the company confirms directly in part
informacyjnej swojego serwisu.

However, one name did come up. In a statement from November 2, 2020, ODI
announced the conclusion of a supply agreement with CC Pharma GmbH, a German subsidiary
of the Canadian Aphria, for five years and a minimum of 1200 kilograms per year, totaling 6000
kilograms. The agreement granted ODI exclusive rights to sell in Poland a specified set of
products under two brands at once. Earlier, in January 2020, the company
informed about Aphria obtaining an EU-GMP certificate for the production of substances
czynnej.

Later materials from ODI do not return to any breeder name. The Stockholm analytical
house Analyst Group writes in its report that the goods come from a Canadian
Tilraya, but this is the analyst's finding, not a statement
from the supplier itself. Tilray sells fourteen strains under its own
label in Polish pharmacies, so the same name would then appear on both sides of the shelf.

Which strains from ODI Pharma reach Polish pharmacies?

Under its own label, one: Jean Guy. Besides it, our list includes thirteen
odmian sygnowanych przez Synoptis Pharma, a Synoptis od sierpnia 2023 roku bierze
dried flowers from only one source, which is ODI. The name on the packaging does not reveal this,
as it refers to the responsibility for the item.

ODI's own entry is named Cannabis flos ODI Pharma and is delivered to pharmacies in
ten-gram packages. In our collection of pharmaceutical entries, it is described by
one record. The same strain is also supplied by the manufacturer S-LAB under a separate registration name, so for one plant
there are two different entries in the list.

The table below compares both sides of this arrangement: the sole entry from ODI and the strains,
which is signed in pharmacies Synoptis Pharma.
The third column provides the terpene indicated for a given entry by the pharmacy database
of comparisons from which this cluster is built.

The exclusivity agreement pertains to supplies, not labeling, so it cannot be determined from the packaging alone
which way a specific batch came. Two strains from this thirteen
have a different leading terpene at Synoptis than the one assigned to the entire
strain: Frosted Cherry Cookies and Master Kush. The current shelf state leads
a summary of available strains, and the store category
drought includes products from retail trade and does not mix with
the pharmacy items described above.

What does the producer's name on the pharmacy packaging actually say?

It states who is responsible for the registration entry, not who cultivated the plant. The entity from
the label reported the product for trade and is responsible for the quality of the batch and for the documentation.
The place of cultivation, the name of the grower, and the country of harvest are not part of this name and do not
have to appear anywhere on the box.

The ODI case shows this in its extreme form. The company does not have its own plantation, yet
its name appears on the label of one item because it has taken on the role of
responsible for the product. At the same time, the goods it passes on are sent to
pharmacies under the banner of another entity, and no one records this flow on the packaging.

The registration name itself is, by the way, poor. It does not contain the strain name, only the type
of raw material, the entity, and the declared contents. The strain name lives solely in the listings
of trade, and these can be inconsistent. The service weedweek.pl described this item twice
in October 2023 as Bienville, with the note that this strain was previously present
on the Polish market as Jean Guy, and in January 2024 as Jean Guy with
with the same Bienville.

For the prescription reader, one thing follows from this. The manufacturer's name on the box is
the address of responsibility, not a certificate of origin. The reference point for
repeatability remains the batch number and the assigned test result.

What distinguishes the ODI Pharma raw material from other items in the pharmacy?

From the outside, nothing is verifiable. The differences that can be shown are the name of the entity,
the declared content, and the size of the packaging. The cultivation process and the drying method are not
publicly described either by ODI or by other producers present in
Polish pharmacies. This symmetry is, in itself, an answer.

The declaration of contents along with its margin remains verifiable. For the ODI item
The manufacturer provides one value, and the permissible deviation reaches one-tenth of it.
in both directions, resulting in a range of 18.0-22.0% THC. The S-LAB position with the same strain name.
declares less and falls within the range of 16.2-19.8% THC. The same plant on two.
shelves is therefore not the same product in terms of declarations.

The rest is promotional material. The statement about sourcing raw material from global leaders.
in the industry, which stands on the ODI side, is not a fact: it does not provide either the breeder's name or.
the country of harvest, nor the cultivation method. Similar assurances of the highest quality are used.
by all suppliers in this market, and none of them can be verified without insight into.
the series documentation.

There is also a difference that does not reflect well on either side. The base budcare.pl.
assigns both positions Jean Guy, the one from ODI and the one from S-LAB, exactly the same set.
of four shares, although the declared strength and described genetic type are different.
The profile is attached to the strain name, not measured for position. Four
The numbers that this base provides here sum up to fifty.
percent, so the denominator remains unknown.

What is known, and what is not known about the ODI Pharma raw material?

It is known who is responsible for the position, how much THC is declared, and in what packaging the dried flower.
reaches the pharmacy. It is unknown who cultivated it, in which country, and under what conditions.
ODI does not publish studies of its own raw material, and no clinical work identifies.
suszu po nazwie dostawcy.

The documentation reveals little more than what is stated on the box. For each batch.
a test result is issued, but it goes to the wholesaler and to the pharmacy, not to.
the public register, so the patient cannot compare two batches of the same position.
The category of issuance remains transparent and uniform across the market.

Separately stands what is promotional material. ODI's declarations about quality and.
partners from the first league of the industry describe intention, not measurement. Patient testimonials.
circulating on forums usually concern the strain name, not the registration position, so.
they lump together the goods of two different manufacturers, which is most evident with the Jean Guy.
strain.

Finally, there is something that no one knows except the company: through whose hands the.
dried flower sold under the Synoptis label passes. A statement from August 2023 says that.
Synoptis sources this raw material exclusively from ODI, while ODI states that it does not.
cultivate. The last link in this chain has not been made public anywhere.
news and we cannot indicate it.

How long does it take for this dried flower to take effect and how long does the effect last?

Just like any other dried flower, as the course is determined by the method of administration, not
the supplier's name. Neither for the ODI Pharma products nor for any of the Synoptis products is there
a separate study on the duration of action published, so the ranges below describe the method
of administration, not this specific product.

The gap between the methods of administration is greater than the entire difference between the two
products of the same strain. The ranges below diverge by hours, and the declarations
of both versions of Jean Guy differ by a few percentage points.

The route of administration determines the course more than the variety itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two hours, and the episode can last six, sometimes eight hours. Hence the most common mistake with oral administration: anyone who thinks nothing is happening after thirty minutes and takes another dose will receive both doses at once. The above ranges describe the route of administration, not this variety; pharmacokinetic studies for a single cultivar have not been published.

What adverse effects have been reported after using ODI Pharma raw material?

No separate ones for this supplier. Reports are conducted for the medicinal product
with a specific batch number, not for the name of the company that supplied the raw material. With
products marked by Synoptis, the name ODI does not appear on the labeling at all,
so there is nothing to associate it with.

For the Polish market, there is no public compilation that breaks down reports by
manufacturers, so comparing ODI products with those from another supplier of the same strain is not
possible even approximately. The report is directed to a doctor or pharmacist, and
formally to the Office for Registration of Medicinal Products, and it is the batch number from the packaging
that is the decisive information.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

Frequently asked questions about ODI Pharma

Does ODI Pharma cultivate hemp?

No. The company states on its own website that it does not intend to cultivate the raw material independently and sources it from industry partners, which it does not name here.

How many ODI Pharma items are available in Polish pharmacies under its own name?

One, the Jean Guy strain, listed as Cannabis flos ODI Pharma. This same strain also has a second, separate registration item, branded by the manufacturer S-LAB.

Does the dried flower sold under the Synoptis Pharma label come from ODI Pharma?

The agreement announced on August 7, 2023, makes ODI the exclusive supplier of hemp dried flower for Synoptis Pharma for five years, with an option to extend for another three and a half years. The labeling of a single package neither confirms nor denies this.

Who owns Synoptis Pharma?

It belongs to the NEUCA group. ODI itself states this in the announcement about the agreement, describing the partner as part of the second largest entity in the Polish healthcare sector.

Why is the grower's name not on the packaging?

Because the registration name indicates the entity responsible for the item, not the place of cultivation. None of the suppliers in our list includes the grower in the name of their item.

Are Jean Guy and Bienville the same strain?

According to the website weedweek.pl, yes. It described the same dried flower ODI once under the name Bienville and once under the name Jean Guy, each time noting that it refers to the same product. Our list lists it under the name Jean Guy.

Does ODI Pharma publish the results of its raw material research?

We did not come across such a publication. The company announces its sales results and information about contracts, while the analytical results of individual batches go to wholesalers and pharmacies, not to the public register.

Dried flower is a pharmaceutical raw material dispensed exclusively by prescription,
in the Rpw category. The material is informational in nature and does not replace medical advice or
farmaceuty. Tekst redakcyjny: ubocha.